One of the main benefits touted by Lilly is that Strattera is the only ADHD drug on the market that is not a stimulant, meaning users are less likely to abuse it. The makers of Adderall and Concerta ...

Lilly spokesperson Jennifer Bunselmeyer said, "They were two cases that the FDA felt were drug-related and that we felt were drug-related as well." According to Lilly's Web site, where the warning ...

(CN) - The Federal Circuit extended an order temporarily blocking generic versions of Eli Lilly & Co.'s Strattera while the pharmaceutical giant appeals a ruling invalidating its U.S. patent for the ...

The Food and Drug Administration warned doctors Thursday about reports of suicidal thinking in some children and adolescents who are taking Strattera, a drug used to treat attention deficit ...

The Food and Drug Administration (FDA) is advising health care professionals about a new warning for Strattera, a drug approved for attention deficit hyperactivity disorder (ADHD) in adults and ...

FDA approves generic forms of Strattera The generic forms of Strattera are the first to be approved by the FDA for the treatment of ADHD. The US Food and Drug Administration (FDA) has approved the ...

WASHINGTON - The Food and Drug Administration warned doctors Thursday about reports of suicidal thinking in some children and adolescents who are taking Strattera, a drug used to treat attention ...

The US Food and Drug Administration (FDA) has approved the first generic versions of Strattera (atomoxetine, Eli Lilly) to treat children and adults with attention ...

May 11, 2005 — The U.S. Food and Drug Administration (FDA) approved in February revisions to safety labeling to advise that use of atomoxetine HCl may be linked rarely to severe liver injury, and that ...

INDIANAPOLIS The U.S. District Court for the District of New Jersey has ruled against drug maker Eli Lilly in its patent infringement case against generic drug maker Actavis regarding a drug used to ...

Eli Lilly & Co. received Food and Drug Administration approval for two new drugs, including a potentially significant treatment for ADHD. Unlike the other ...